ReviewInternational journal of oncology2014
Emerging targeted therapies for melanoma treatment (review).
Review in International journal of oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Bridging gaps throughout a patient's journey with melanoma: a systematic review.Melanoma management · 2025Review
- Review
- Has the development of cancer biomarkers to guide treatment improved health outcomes?The European journal of health economics : HEPAC : health economics in prevention and care · 2021Article
- Evolving impact of long-term survival results on metastatic melanoma treatment.Journal for immunotherapy of cancer · 2020Review
- Vitamin D and its low calcemic analogs modulate the anticancer properties of cisplatin and dacarbazine in the human melanoma A375 cell line.International journal of oncology · 2019Article
- BRAF immunohistochemistry predicts sentinel lymph node involvement in intermediate thickness melanomas.PloS one · 2019Article
- Kushui Rose (R. Setate x R. Rugosa) decoction exerts antitumor effects in C. elegans by downregulating Ras/MAPK pathway and resisting oxidative stress.International journal of molecular medicine · 2018Article
- FOXP3 expression is modulated by TGF‑β1/NOTCH1 pathway in human melanoma.International journal of molecular medicine · 2018Article
- Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.Frontiers in pharmacology · 2018Review
- A Misleading Anamnesis: Learning To Suspect.Open access Macedonian journal of medical sciences · 2017Article
- Late Onset Achromatic Melanoma Arising in a Giant Congenital Melanocytic Nevus.Open access Macedonian journal of medical sciences · 2017Article
- Standardization of A375 human melanoma models on chicken embryo chorioallantoic membrane and Balb/c nude mice.Oncology reports · 2017Article
- Growth Hormone Receptor Knockdown Sensitizes Human Melanoma Cells to Chemotherapy by Attenuating Expression of ABC Drug Efflux Pumps.Hormones & cancer · 2017Article
- NF‑κB inhibition is associated with OPN/MMP‑9 downregulation in cutaneous melanoma.Oncology reports · 2017Article
- Detailed simulation of cancer exome sequencing data reveals differences and common limitations of variant callers.BMC bioinformatics · 2017Article
- Metastatic Melanoma: Treatment and Survival in the US after the Introduction of Ipilimumab and Vemurafenib.Oncology research and treatment · 2017Article
- Hmgb1 inhibits Klotho expression and malignant phenotype in melanoma cells by activating NF-κB.Oncotarget · 2016Article
- Genetics and epigenetics of melanoma.Oncology letters · 2016Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous melanoma is an aggressive cancer with a poor prognosis for patients with advanced disease. The identification of several key molecular pathways implicated in the pathogenesis of melanoma has led to the development of novel therapies for this devastating disease. In melanoma, both the Ras/Raf/MEK/ERK (MAPK) and the PI3K/AKT (AKT) signalling pathways are constitutively activated through multiple mechanisms. Targeting various effectors of these pathways with pharmacologic inhibitors may inhibit melanoma cell growth and angiogenesis. Ongoing clinical trials provide hope to improve progression-free survival of patients with advanced melanoma. This review summarizes the most relevant studies focused on the specific action of these new molecular targeted agents. Mechanisms of resistance to therapy are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.